Psyence Biomedical Ltd.
PBM · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $2,386 | $3,900,553 | $164,612,245 | $152,282,830 |
| - Cash | $6,135 | $763 | $129 | $648 |
| + Debt | $0 | $10,448 | $685 | $0 |
| Enterprise Value | -$3,749 | $3,910,238 | $164,612,802 | $152,282,182 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$4 | -$0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | $1,025 | -$51,106 | -$1,294 | -$334 |
| % Margin | – | – | – | – |
| Net Income | $1,012 | -$51,159 | $8,014 | $8,230 |
| % Margin | – | – | – | – |
| EPS Diluted | 1.78 | -7.85 | -0.64 | 0.25 |
| % Growth | 122.7% | -1,126.6% | -356% | – |
| Operating Cash Flow | -$3,734 | -$2,945 | -$520 | -$839 |
| Capital Expenditures | -$10 | -$6 | $0 | $0 |
| Free Cash Flow | -$3,744 | -$2,951 | -$520 | -$839 |